TF-2 plus RDC-018 peptide (Immunomedics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTF-2 plus RDC-018 peptide (Immunomedics)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant polypeptideRadiation-emitting products +[4]

Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 modulators

TargetsCarcinoembryonic antigen related cell adhesion molecule 5

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesImmunomedics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunomedics Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A